LEKTI Antibody (6A108): sc-71511
- LEKTI Antibody (6A108) is a mouse monoclonal IgG1 provided at 200 µg/ml
- raised against recombinant LEKTI of human origin
- recommended for detection of precursor and mature LEKTI (specifically domains 1-6, 6-9, 9-12 and weakly with domains 13-15) of human origin by WB, IP and IF
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for LEKTI Antibody (6A108). This work is in progress.
QUICK LINKS
SEE ALSO...
LEKTI Antibody (6A108) is a mouse monoclonal IgG1 antibody that detects Lympho-epithelial Kazal-type inhibitor (LEKTI) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). LEKTI plays a crucial role as a serine protease inhibitor, providing essential protection to mucous epithelia against microbial invasion and inflammation, which is vital for maintaining the integrity of epithelial barriers. LEKTI (6A108) antibody recognizes protein predominantly located in the granular and uppermost spinous layers of the epidermis, as well as in the differentiated layers of stratified epithelia, highlighting its importance in epithelial differentiation and function. Notably, mutations in the SPINK5 gene, which encodes LEKTI, are linked to Netherton syndrome, a severe autosomal recessive disorder that manifests with symptoms such as atopic dermatitis and hay fever, underscoring the significance of LEKTI in skin health and disease. Anti-LEKTI antibody (6A108) serves as an invaluable tool for researchers studying epithelial biology and related pathologies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
LEKTI Antibody (6A108) References:
- LEKTI demonstrable by immunohistochemistry of the skin: a potential diagnostic skin test for Netherton syndrome. | Ong, C., et al. 2004. Br J Dermatol. 151: 1253-7. PMID: 15606522
- Consequences of C-terminal domains and N-terminal signal peptide deletions on LEKTI secretion, stability, and subcellular distribution. | Jayakumar, A., et al. 2005. Arch Biochem Biophys. 435: 89-102. PMID: 15680911
- Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). | Schechter, NM., et al. 2005. Biol Chem. 386: 1173-84. PMID: 16307483
- hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. | Egelrud, T., et al. 2005. Br J Dermatol. 153: 1200-3. PMID: 16307658
- SPINK5, the defective gene in netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing. | Tartaglia-Polcini, A., et al. 2006. J Invest Dermatol. 126: 315-24. PMID: 16374478
- New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI. | Bennett, K., et al. 2010. J Proteome Res. 9: 4289-94. PMID: 20533828
- Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. | Di, WL., et al. 2011. Mol Ther. 19: 408-16. PMID: 20877344
- Lekti immunochemistry for the diagnosis of netherton syndrome. | Leclerc-Mercier, S., et al. 2012. Am J Dermatopathol. 34: 853. PMID: 22534635
- The identification of a new role for LEKTI in the skin: The use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome. | Bennett, K., et al. 2012. J Proteomics. 75: 3925-37. PMID: 22588119
- Lobelia chinensis Extract and Its Active Compound, Diosmetin, Improve Atopic Dermatitis by Reinforcing Skin Barrier Function through SPINK5/LEKTI Regulation. | Park, NJ., et al. 2022. Int J Mol Sci. 23: PMID: 35955819
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LEKTI Antibody (6A108) | sc-71511 | 200 µg/ml | $322.00 |